Johnson & Johnson Medical Devices has rebranded as Johnson & Johnson MedTech as the unit moves deeper into digital technology.
New Brunswick, New Jersey–based Johnson & Johnson (NYSE: JNJ) noted the coming change in its 2022 annual report published last month, saying the switch would take effect in the company’s first fiscal quarter.
That preview was followed by a March 7 announcement of approximately 100 words, mostly attributed to Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy.

Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]
Johnson & Johnson provided more information to Medical Design & Outsourcing today,
“We unleash diverse healthcare expertise, purposeful technology, and a passion for people to empower everyone to live their best life possible,” the company said in a statement. “At Johnson & Johnson MedTech, we go beyond what’s next to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.”
That sounds an awful lot like what Medical Devices — I mean, MedTech — Group CIO and Global VP Larry Jones and Office of Digital Innovation Leader Peter Schulam had to say about the future of the company and the medtech industry when I spoke with them recently about the power of the cloud in the wake of Johnson & Johnson’s deal with Microsoft (Nasdaq: MSFT).
Johnson & Johnson is the second-largest medtech company in the world, according to Medical Design & Outsourcing‘s latest Medtech Big 100 ranking.
The Johnson & Johnson MedTech segment covers interventional solutions, orthopedics, surgery and vision, with brand names such as Biosense Webster, Cerenovus, DePuy Synthes, Ethicon, Acclarent and Acuvue.
Endiatx “ehn-dee-ah-tix” combines Endoscopy, Diagnostics, and the Tx is for Treatment